J
Jungwoo Kim
Researcher at California Institute of Technology
Publications - 26
Citations - 1964
Jungwoo Kim is an academic researcher from California Institute of Technology. The author has contributed to research in topics: Medicine & T cell. The author has an hindex of 10, co-authored 18 publications receiving 1555 citations. Previous affiliations of Jungwoo Kim include Cornell University.
Papers
More filters
Journal ArticleDOI
Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase.
Jintang Du,Yeyun Zhou,Xiaoyang Su,Jiujiu Yu,Saba Khan,Hong Jiang,Jungwoo Kim,Jimin Woo,Jun Huyn Kim,Brian Hyun Choi,Bin He,Wei Chen,Sheng Zhang,Richard A. Cerione,Johan Auwerx,Quan Hao,Quan Hao,Hening Lin +17 more
TL;DR: It is found that Sirt5 is an efficient protein lysine desuccinylase and demalonylase in vitro and may represent a posttranslational modification that can be reversed by Sirt 5 in vivo.
Journal ArticleDOI
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.
Yapeng Su,Wei Wei,Wei Wei,Lidia Robert,Min Xue,Jennifer Tsoi,Angel Garcia-Diaz,Blanca Homet Moreno,Blanca Homet Moreno,Jungwoo Kim,Rachel Ng,Jihoon W. Lee,Richard C. Koya,Begonya Comin-Anduix,Thomas G. Graeber,Antoni Ribas,James R. Heath,James R. Heath +17 more
TL;DR: Biophysical insights are provided into how BRAF mutant melanoma cells adapt to the stress of MAPK inhibition via a series of reversible phenotypic transitions toward drug-tolerant or drug-resistant cell states enriched for neural-crest factors and mesenchymal signatures.
Journal ArticleDOI
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
Wei Wei,Wei Wei,Young Shik Shin,Young Shik Shin,Min Xue,Tomoo Matsutani,Kenta Masui,Huijun Yang,Shiro Ikegami,Yuchao Gu,Ken Herrmann,Dazy Johnson,Xiangming Ding,Kiwook Hwang,Jungwoo Kim,Jian Zhou,Yapeng Su,Xin-Min Li,Bruno Bonetti,Rajesh Chopra,C. David James,Webster K. Cavenee,Timothy F. Cloughesy,Paul S. Mischel,James R. Heath,James R. Heath,Beatrice Gini +26 more
TL;DR: Single-cell phosphoproteomics is performed on a patient-derived in vivo GBM model of mTOR kinase inhibitor resistance and coupled it to an analytical approach for detecting changes in signaling coordination to identify actionable alterations in signal coordination that underlie adaptive resistance.
Journal ArticleDOI
Gene-targeted microfluidic cultivation validated by isolation of a gut bacterium listed in Human Microbiome Project's Most Wanted taxa
Liang Ma,Jungwoo Kim,Roland Hatzenpichler,Mikhail A. Karymov,Nathaniel Hubert,Ira M. Hanan,Eugene B. Chang,Rustem F. Ismagilov +7 more
TL;DR: Isolate microfluidicus 1 is, to the authors' knowledge, the first successful example of targeted cultivation of a microorganism from the high-priority group of the Human Microbiome Project’s “Most Wanted” list, and the first cultured representative of a previously unidentified genus of the Ruminococcaceae family.
Journal ArticleDOI
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Patrick Y. Wen,Patrick Y. Wen,Mehdi Touat,Mehdi Touat,Brian M. Alexander,Brian M. Alexander,Ingo K. Mellinghoff,Shakti Ramkissoon,Christine McCluskey,Kristine Pelton,Sam Haidar,Sankha S. Basu,Sankha S. Basu,Sarah C. Gaffey,Loreal Brown,Juan Emmanuel Martinez-Ledesma,Shaofang Wu,Jungwoo Kim,Wei Wei,Wei Wei,Mi-Ae Park,Jason T. Huse,John G. Kuhn,Mikael L. Rinne,Mikael L. Rinne,Howard Colman,Nathalie Y. R. Agar,Nathalie Y. R. Agar,Antonio Omuro,Lisa M. DeAngelis,Mark R. Gilbert,John de Groot,Timothy F. Cloughesy,Andrew S. Chi,Thomas M. Roberts,Jean J. Zhao,Eudocia Q. Lee,Eudocia Q. Lee,Lakshmi Nayak,Lakshmi Nayak,James R. Heath,Laura L. Horky,Tracy T. Batchelor,Rameen Beroukhim,Rameen Beroukhim,Susan M. Chang,Azra H. Ligon,Ian F. Dunn,Dimpy Koul,Geoffrey S. Young,Michael D. Prados,David A. Reardon,David A. Reardon,W. K. Alfred Yung,Keith L. Ligon,Keith L. Ligon +55 more
TL;DR: Although buparlisib achieved significant brain penetration, the lack of clinical efficacy was explained by incomplete blockade of the PI3K pathway in tumor tissue, and integrative results suggest that additional study ofPI3K inhibitors that achieve more-complete pathway inhibition may still be warranted.